The FDA approved Infilbray, or venglustat, for neurological symptoms of type 3 Gaucher disease. The once-daily pill improved trial participants’ neurological scores but carries serious warnings.
Oral Infilbray Wins Early FDA Approval as First Treatment for Brain-Related Symptoms of Type 3 Gaucher Disease
by | Nov 19, 2026 | Uncategorized | 0 comments

Recent Comments